WHO Clinical Molecular and Pathological (WHO-CMP) Features of Congenital MPLS505N and the Acquired MPLW515l/K Mutated Essential Thrombocythemia and Myelofibrosis

Jan Jacques Michiels^1*, Achille PICH², Hendrik De Raeve³, Vitr Camp⁴ and Jiri Schwarz⁴

¹Goodheart Institute & Foundation, Rotterdam and International collaborations and Research on Myeloproliferative neoplasms and related Disorders (ICAR.MPNr), Erasmus Tower, Veenmos 13 3069 AT Rotterdam, The Netherlands

²2Department of Molecular Biotechnology and Health Sciences, Section of Pathology, University of Turin, Via Santena 7 , I-10126 Torino, Italy

³Department of Pathology, OLVG Hospital Aalst and University of Brussels, Belgium

⁴Department of Pathology and Institute of Hematology & Blood Transfusion, U nemocnice 1. CZ-128 20 Prague 2, Czechia, United Kingdom

^*Corresponding Author: Jan Jacques Michiels, Senior Internist & Investigator, Goodheart Institute & Foundation, Rotterdam and International collaborations and Research on Myeloproliferative neoplasms and related Disorders (ICAR.MPNr)., Erasmus Tower, Veenmos 13 3069 AT Rotterdam, The Netherlands, Tel: +316-26970534 Email: